Laminar Pharma Announces “Last Patient, Last Visit” in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit...

